FDA authorized J&J's OTTAVA robot for sleeve and bypass

What happened

Johnson and Johnson announced July 22, 2026 that the FDA granted De Novo marketing authorization for the OTTAVA Robotic Surgical System, which the company describes as the world's first table-integrated soft tissue robotic system. The authorization covers multiple procedures in general surgery within the upper abdomen, and the company's list explicitly includes two of the most common bariatric operations: Roux-en-Y gastric bypass and gastric sleeve (sleeve gastrectomy). Also on the authorized list are gastrectomy, cholecystectomy, splenectomy, small bowel resection, appendectomy, lysis of adhesions, fundoplication, and hiatal hernia repair.

The path to authorization was long by current device-review standards: Johnson and Johnson submitted the De Novo application on January 7, 2026. The company says it will launch commercially with select U.S. customers first, focusing on early adoption while it works in parallel toward additional indications and regulatory jurisdictions. A U.S. clinical trial of OTTAVA in inguinal hernia repair is ongoing. Company executives framed the system around operating-room integration and workflow rather than head-to-head outcome claims.

For bariatric surgery specifically, the authorization adds a second major soft-tissue robotics platform with sleeve gastrectomy and Roux-en-Y bypass explicitly in its authorized indications, alongside the incumbent systems many centers already use for robotic bariatric cases. What the authorization does not include is any clinical-performance claim: De Novo marketing authorization means the FDA found the system reasonably safe and effective for these general-surgery uses, not that robotic sleeve or bypass outperforms standard laparoscopy.

What it means

Patients do not choose a robot the way they choose a procedure. The surgeon, the operation, and the aftercare drive outcomes far more than the brand of console in the room. For hospitals already running robotic bariatric programs, OTTAVA is a second platform option; for patients, nothing about this authorization changes which operation is appropriate for them or how quickly they should have it.

What it does not mean

This is not evidence that robotic sleeve or bypass beats laparoscopy for weight loss, safety, or conversion rates; De Novo authorization permits a device to be marketed, it makes no comparative performance claim, and no published outcome data exist yet for OTTAVA in bariatric procedures. It is not a reason to delay a scheduled operation in hopes of a new robot. The desk does not have the FDA decision summary, so the authorized-procedure scope rests on Johnson and Johnson's own list rather than the agency text. Initial availability is limited to select customers and will take time to spread. This is a device-market-access story, not an outcomes story.